Rachel B Jones1, Shunsuke Furuta1, Jan Willem Cohen Tervaert2, Thomas Hauser3, Raashid Luqmani4, Matthew D Morgan5, Chen Au Peh6, Caroline O Savage5, Marten Segelmark7, Vladimir Tesar8, Pieter van Paassen2, Michael Walsh9, Kerstin Westman10, David Rw Jayne1. 1. Renal Unit, Addenbrooke's Hospital, Cambridge, UK. 2. Clinical and Experimental Immunology, Maastricht University, Maastricht, The Netherlands. 3. IZZ Immunologie-Zentrum Zürich, Zürich, Switzerland. 4. Department of Rheumatology, Nuffield Orthopaedic Centre, Oxford, UK. 5. Department of Renal Immunobiology, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. 6. Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia. 7. Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 8. The First Faculty of Medicine, Charles University, Prague, Czech Republic. 9. Departments of Medicine (Nephrology) and Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Canada. 10. Department of Nephrology and Transplantation in Malmo, University Hospital of Skane and Lund University, Malmo, Sweden.
Abstract
OBJECTIVES: The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown. METHODS:Forty-four patients with newly diagnosed ANCA-associated vasculitis and renal involvement were randomised, 3:1, to glucocorticoids plus either rituximab (375 mg/m(2)/week×4) with two intravenous cyclophosphamide pulses (n=33, rituximab group), or intravenous cyclophosphamide for 3-6 months followed by azathioprine (n=11, control group). RESULTS: The primary end point at 24 months was a composite of death, end-stage renal disease and relapse, which occurred in 14/33 in the rituximab group (42%) and 4/11 in the control group (36%) (p=1.00). After remission induction treatment all patients in the rituximab group achieved complete B cell depletion and during subsequent follow-up, 23/33 (70%) had B cell return. Relapses occurred in seven in the rituximab group (21%) and two in the control group (18%) (p=1.00). All relapses in the rituximab group occurred after B cell return. CONCLUSIONS: At 24 months, rates of the composite outcome of death, end-stage renal disease and relapse did not differ between groups. In the rituximab group, B cell return was associated with relapse. TRIAL REGISTRATION NUMBER: ISRCTN28528813. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RCT Entities:
OBJECTIVES: The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown. METHODS: Forty-four patients with newly diagnosed ANCA-associated vasculitis and renal involvement were randomised, 3:1, to glucocorticoids plus either rituximab (375 mg/m(2)/week×4) with two intravenous cyclophosphamide pulses (n=33, rituximab group), or intravenous cyclophosphamide for 3-6 months followed by azathioprine (n=11, control group). RESULTS: The primary end point at 24 months was a composite of death, end-stage renal disease and relapse, which occurred in 14/33 in the rituximab group (42%) and 4/11 in the control group (36%) (p=1.00). After remission induction treatment all patients in the rituximab group achieved complete B cell depletion and during subsequent follow-up, 23/33 (70%) had B cell return. Relapses occurred in seven in the rituximab group (21%) and two in the control group (18%) (p=1.00). All relapses in the rituximab group occurred after B cell return. CONCLUSIONS: At 24 months, rates of the composite outcome of death, end-stage renal disease and relapse did not differ between groups. In the rituximab group, B cell return was associated with relapse. TRIAL REGISTRATION NUMBER: ISRCTN28528813. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
B cells; Cyclophosphamide; Granulomatosis with polyangiitis; Systemic vasculitis; Treatment
Authors: Sebastian Unizony; Miguel Villarreal; Eli M Miloslavsky; Na Lu; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cg M Kallenberg; E William St Clair; David Ikle; Nadia K Tchao; Linna Ding; Paul Brunetta; Hyon K Choi; Paul A Monach; Fernando Fervenza; John H Stone; Ulrich Specks Journal: Ann Rheum Dis Date: 2015-11-30 Impact factor: 19.103
Authors: N Venhoff; F Proft; H Schulze-Koops; J Holle; R E Voll; C Iking-Konert; A M Jacobi; J Henes; L Unger; O Kneitz; T Dörner; J Thiel Journal: Z Rheumatol Date: 2018-02 Impact factor: 1.372
Authors: Dragana Odobasic; Virginie Oudin; Kenji Ito; Poh-Yi Gan; A Richard Kitching; Stephen R Holdsworth Journal: J Am Soc Nephrol Date: 2019-08-23 Impact factor: 10.121
Authors: Debra Boyer; Carey C Thomson; Robyn Cohen; Devika Rao; Sharon Dell; Jonathan Rayment; Ruobing Wang; Fei J Dy; Jennifer Wambach; Jade Tam-Williams; Dawn Simon; Eric Price; Christopher M Oermann; Alvin Singh; Jordan S Rettig; Elizabeth D Duncan; Christopher D Baker; Deborah R Liptzin; Paul E Moore Journal: Ann Am Thorac Soc Date: 2016-06